215 related articles for article (PubMed ID: 33992645)
1. Structural basis for CD97 recognition of the decay-accelerating factor CD55 suggests mechanosensitive activation of adhesion GPCRs.
Niu M; Xu S; Yang J; Yao D; Li N; Yan J; Zhong G; Song G
J Biol Chem; 2021; 296():100776. PubMed ID: 33992645
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97.
Hamann J; Stortelers C; Kiss-Toth E; Vogel B; Eichler W; van Lier RA
Eur J Immunol; 1998 May; 28(5):1701-7. PubMed ID: 9603477
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex.
Lin HH; Stacey M; Saxby C; Knott V; Chaudhry Y; Evans D; Gordon S; McKnight AJ; Handford P; Lea S
J Biol Chem; 2001 Jun; 276(26):24160-9. PubMed ID: 11297558
[TBL] [Abstract][Full Text] [Related]
4. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF).
Hamann J; Vogel B; van Schijndel GM; van Lier RA
J Exp Med; 1996 Sep; 184(3):1185-9. PubMed ID: 9064337
[TBL] [Abstract][Full Text] [Related]
5. Biochemical features of the adhesion G protein-coupled receptor CD97 related to its auto-proteolysis and HeLa cell attachment activities.
Yang LY; Liu XF; Yang Y; Yang LL; Liu KW; Tang YB; Zhang M; Tan MJ; Cheng SM; Xu YC; Yang HY; Liu ZJ; Song GJ; Huang W
Acta Pharmacol Sin; 2017 Jan; 38(1):56-68. PubMed ID: 27641734
[TBL] [Abstract][Full Text] [Related]
6. Molecular cloning and characterization of mouse CD97.
Hamann J; van Zeventer C; Bijl A; Molenaar C; Tesselaar K; van Lier RA
Int Immunol; 2000 Apr; 12(4):439-48. PubMed ID: 10744645
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).
Qian YM; Haino M; Kelly K; Song WC
Immunology; 1999 Oct; 98(2):303-11. PubMed ID: 10540231
[TBL] [Abstract][Full Text] [Related]
8. Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis.
Visser L; de Vos AF; Hamann J; Melief MJ; van Meurs M; van Lier RA; Laman JD; Hintzen RQ
J Neuroimmunol; 2002 Nov; 132(1-2):156-63. PubMed ID: 12417446
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55.
Abbott RJ; Spendlove I; Roversi P; Fitzgibbon H; Knott V; Teriete P; McDonnell JM; Handford PA; Lea SM
J Biol Chem; 2007 Jul; 282(30):22023-32. PubMed ID: 17449467
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of CD97 and CD55 levels in the differential diagnosis of tuberculous and malignant pleural effusions.
Wang C; Jie J; Li D; Liu Y; Gao J; Song L
Medicine (Baltimore); 2021 Jul; 100(30):e26771. PubMed ID: 34397724
[TBL] [Abstract][Full Text] [Related]
11. N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding.
Wobus M; Vogel B; Schmücking E; Hamann J; Aust G
Int J Cancer; 2004 Dec; 112(5):815-22. PubMed ID: 15386373
[TBL] [Abstract][Full Text] [Related]
12. The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma.
Han SL; Xu C; Wu XL; Li JL; Liu Z; Zeng QQ
Int J Colorectal Dis; 2010 Jun; 25(6):695-702. PubMed ID: 20339853
[TBL] [Abstract][Full Text] [Related]
13. Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells.
Kwakkenbos MJ; Pouwels W; Matmati M; Stacey M; Lin HH; Gordon S; van Lier RA; Hamann J
J Leukoc Biol; 2005 Jan; 77(1):112-9. PubMed ID: 15498814
[TBL] [Abstract][Full Text] [Related]
14. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue.
Hamann J; Wishaupt JO; van Lier RA; Smeets TJ; Breedveld FC; Tak PP
Arthritis Rheum; 1999 Apr; 42(4):650-8. PubMed ID: 10211878
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD97 and CD55 in human medullary thyroid carcinomas.
Mustafa T; Klonisch T; Hombach-Klonisch S; Kehlen A; Schmutzler C; Koehrle J; Gimm O; Dralle H; Hoang-Vu C
Int J Oncol; 2004 Feb; 24(2):285-94. PubMed ID: 14719104
[TBL] [Abstract][Full Text] [Related]
16. Interactions of CD55 with non-complement ligands.
Lea S
Biochem Soc Trans; 2002 Nov; 30(Pt 6):1014-9. PubMed ID: 12440964
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma.
Wu J; Lei L; Wang S; Gu D; Zhang J
J Biomed Biotechnol; 2012; 2012():587672. PubMed ID: 22547928
[TBL] [Abstract][Full Text] [Related]
18. Costimulation via CD55 on human CD4+ T cells mediated by CD97.
Capasso M; Durrant LG; Stacey M; Gordon S; Ramage J; Spendlove I
J Immunol; 2006 Jul; 177(2):1070-7. PubMed ID: 16818763
[TBL] [Abstract][Full Text] [Related]
19. The role of ADGRE5/CD97 in human retinal pigment epithelial cell growth and survival.
Eichler W; Lohrenz A; Simon KU; Krohn S; Lange J; Bürger S; Liebscher I
Ann N Y Acad Sci; 2019 Nov; 1456(1):64-79. PubMed ID: 31397926
[TBL] [Abstract][Full Text] [Related]
20. Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients.
Liu Y; Chen L; Peng SY; Chen ZX; Hoang-Vu C
J Zhejiang Univ Sci B; 2005 Sep; 6(9):913-8. PubMed ID: 16130195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
